<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Projects on Junyi Zhou</title>
    <link>/projects/</link>
    <description>Recent content in Projects on Junyi Zhou</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en</language>
    <lastBuildDate>Mon, 19 Apr 2021 00:00:00 +0000</lastBuildDate><atom:link href="/projects/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>Clustering Longitudinal Data (Online App)</title>
      <link>/projects/clusterlongapp/</link>
      <pubDate>Mon, 19 Apr 2021 00:00:00 +0000</pubDate>
      
      <guid>/projects/clusterlongapp/</guid>
      <description></description>
    </item>
    
    <item>
      <title>ClusterLong: An R-package to Cluster Longitudinal Data</title>
      <link>/projects/clusterlongpackage/</link>
      <pubDate>Fri, 16 Apr 2021 00:00:00 +0000</pubDate>
      
      <guid>/projects/clusterlongpackage/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Connection between the Idea behind OptTrialDesign &amp; CAPM in Finance</title>
      <link>/projects/odt-capm/</link>
      <pubDate>Wed, 01 Jan 2020 00:00:00 +0000</pubDate>
      
      <guid>/projects/odt-capm/</guid>
      <description>Idea behind OptTrialDesign In Optimal Design Strategy, we propose a novel way to find the optimal trial design, in terms of maximizing the financial outcomes, i.e., Expected Net Revenue (ENR), but also under the regulatory requirements. We have to trade-off because in pharmaceutical companiesâ€™ position, a shorter study/trial duration leads to earlier market access which helps to maximize the profits before LOE (loss of exclusivity). On the other hand, regulatory agencies and health technology assessment (HTA) bodies wish to see a more guaranteed clinical results, which usually require longer study duration.</description>
    </item>
    
    <item>
      <title>Review of Causal Inference</title>
      <link>/projects/proposal/</link>
      <pubDate>Tue, 05 Nov 2019 00:00:00 +0000</pubDate>
      
      <guid>/projects/proposal/</guid>
      <description>Heterogeneous Treatment Effect Estimation 1. Introduction The need for causal inference arises in many different fields. Economists want to quantify the causal effects of interest rate cut on the economy. Trade policy makers want to know whether increased tariff causes changes in trade deficit. Healthcare providers want to assess whether a therapy causes changes in specific patient outcomes. In this proposal, I examine the estimation of causal effects therapeutic treatments by using observational data in a population where the treatment effects vary by observed patient characteristics.</description>
    </item>
    
    <item>
      <title>Optimal Trial Design (Online App)</title>
      <link>/projects/opttrialdesignapp/</link>
      <pubDate>Wed, 28 Aug 2019 00:00:00 +0000</pubDate>
      
      <guid>/projects/opttrialdesignapp/</guid>
      <description></description>
    </item>
    
    <item>
      <title>OptTrialDesign: An R-package for Optimal Trial Design--Balancing between Financial Outcomes and Regulatory Concerns</title>
      <link>/projects/opttrialdesignpackage/</link>
      <pubDate>Mon, 26 Aug 2019 00:00:00 +0000</pubDate>
      
      <guid>/projects/opttrialdesignpackage/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Monte Carlo Optimization</title>
      <link>/projects/mc-opt-slides/</link>
      <pubDate>Wed, 10 Apr 2019 00:00:00 +0000</pubDate>
      
      <guid>/projects/mc-opt-slides/</guid>
      <description>Optimization is the key component of the AI/ML algorithm. Whatever objective function is proposed, the final step is to optimize it. Convex optimization problems, either unconstrained or constrained, are well explored (see here). Even though, the efficiency or performance still largely depends on the shape of the surface of the objective function. For convex problems, the solution could be trapped at saddle points; or for local convex objective functions, the solution might reach to the local optima instead of global optima.</description>
    </item>
    
  </channel>
</rss>
